Centralisation of specialist cancer surgery services in two areas of England: the RESPECT-21 mixed-methods evaluation

Naomi J. Fulop, A. Ramsay, C. Vindrola‐Padros, C. Clarke, R. Hunter, G. Black, Victoria J Wood, M. Melnychuk, C. Perry, L. Vallejo-Torres, P. L. Ng, R. Barod, A. Bex, R. Boaden, Afsana Bhuiya, Veronica Brinton, P. Fahy, J. Hines, C. Levermore, S. Maddineni, Muntzer M. Mughal, K. Pritchard-Jones, J. Sandell, D. Shackley, M. Tran, Steve Morris
{"title":"Centralisation of specialist cancer surgery services in two areas of England: the RESPECT-21 mixed-methods evaluation","authors":"Naomi J. Fulop, A. Ramsay, C. Vindrola‐Padros, C. Clarke, R. Hunter, G. Black, Victoria J Wood, M. Melnychuk, C. Perry, L. Vallejo-Torres, P. L. Ng, R. Barod, A. Bex, R. Boaden, Afsana Bhuiya, Veronica Brinton, P. Fahy, J. Hines, C. Levermore, S. Maddineni, Muntzer M. Mughal, K. Pritchard-Jones, J. Sandell, D. Shackley, M. Tran, Steve Morris","doi":"10.3310/qfgt2379","DOIUrl":null,"url":null,"abstract":"\n \n Centralising specialist cancer surgical services is an example of major system change. High-volume centres are recommended to improve specialist cancer surgery care and outcomes.\n \n \n \n Our aim was to use a mixed-methods approach to evaluate the centralisation of specialist surgery for prostate, bladder, renal and oesophago-gastric cancers in two areas of England [i.e. London Cancer (London, UK), which covers north-central London, north-east London and west Essex, and Greater Manchester Cancer (Manchester, UK), which covers Greater Manchester].\n \n \n \n Stakeholder preferences for centralising specialist cancer surgery were analysed using a discrete choice experiment, surveying cancer patients (n = 206), health-care professionals (n = 111) and the general public (n = 127). Quantitative analysis of impact on care, outcomes and cost-effectiveness used a controlled before-and-after design. Qualitative analysis of implementation and outcomes of change used a multisite case study design, analysing documents (n = 873), interviews (n = 212) and non-participant observations (n = 182). To understand how lessons apply in other contexts, we conducted an online workshop with stakeholders from a range of settings. A theory-based framework was used to synthesise these approaches.\n \n \n \n \n Stakeholder preferences – patients, health-care professionals and the public had similar preferences, prioritising reduced risk of complications and death, and better access to specialist teams. Travel time was considered least important. Quantitative analysis (impact of change) – only London Cancer’s centralisations happened soon enough for analysis. These changes were associated with fewer surgeons doing more operations and reduced length of stay [prostate –0.44 (95% confidence interval –0.55 to –0.34) days; bladder –0.563 (95% confidence interval –4.30 to –0.83) days; renal –1.20 (95% confidence interval –1.57 to –0.82) days]. The centralisation meant that renal patients had an increased probability of receiving non-invasive surgery (0.05, 95% confidence interval 0.02 to 0.08). We found no evidence of impact on mortality or re-admissions, possibly because risk was already low pre-centralisation. London Cancer’s prostate, oesophago-gastric and bladder centralisations had medium probabilities (79%, 62% and 49%, respectively) of being cost-effective, and centralising renal services was not cost-effective (12% probability), at the £30,000/quality-adjusted life-year threshold. Qualitative analysis, implementation and outcomes – London Cancer’s provider-led network overcame local resistance by distributing leadership throughout the system. Important facilitators included consistent clinical leadership and transparent governance processes. Greater Manchester Cancer’s change leaders learned from history to deliver the oesophago-gastric centralisation. Greater Manchester Cancer’s urology centralisations were not implemented because of local concerns about the service model and local clinician disengagement. London Cancer’s network continued to develop post implementation. Consistent clinical leadership helped to build shared priorities and collaboration. Information technology difficulties had implications for interorganisational communication and how reliably data follow the patient. London Cancer’s bidding processes and hierarchical service model meant that staff reported feelings of loss and a perceived ‘us and them’ culture. Workshop – our findings resonated with workshop attendees, highlighting issues about change leadership, stakeholder collaboration and implications for future change and evaluation.\n \n \n \n The discrete choice experiment used a convenience sample, limiting generalisability. Greater Manchester Cancer implementation delays meant that we could study the impact of only London Cancer changes. We could not analyse patient experience, quality of life or functional outcomes that were important to patients (e.g. continence).\n \n \n \n Future research may focus on impact of change on care options offered, patient experience, functional outcomes and long-term sustainability. Studying other approaches to achieving high-volume services would be valuable.\n \n \n \n National Institute for Health and Care Research (NIHR) Clinical Research Network Portfolio reference 19761.\n \n \n \n This project was funded by the NIHR Health and Social Care Delivery Research programme and will be published in full in Health and Social Care Delivery Research; Vol. 11, No. 2. See the NIHR Journals Library website for further project information.\n","PeriodicalId":73204,"journal":{"name":"Health and social care delivery research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health and social care delivery research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3310/qfgt2379","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Centralising specialist cancer surgical services is an example of major system change. High-volume centres are recommended to improve specialist cancer surgery care and outcomes. Our aim was to use a mixed-methods approach to evaluate the centralisation of specialist surgery for prostate, bladder, renal and oesophago-gastric cancers in two areas of England [i.e. London Cancer (London, UK), which covers north-central London, north-east London and west Essex, and Greater Manchester Cancer (Manchester, UK), which covers Greater Manchester]. Stakeholder preferences for centralising specialist cancer surgery were analysed using a discrete choice experiment, surveying cancer patients (n = 206), health-care professionals (n = 111) and the general public (n = 127). Quantitative analysis of impact on care, outcomes and cost-effectiveness used a controlled before-and-after design. Qualitative analysis of implementation and outcomes of change used a multisite case study design, analysing documents (n = 873), interviews (n = 212) and non-participant observations (n = 182). To understand how lessons apply in other contexts, we conducted an online workshop with stakeholders from a range of settings. A theory-based framework was used to synthesise these approaches. Stakeholder preferences – patients, health-care professionals and the public had similar preferences, prioritising reduced risk of complications and death, and better access to specialist teams. Travel time was considered least important. Quantitative analysis (impact of change) – only London Cancer’s centralisations happened soon enough for analysis. These changes were associated with fewer surgeons doing more operations and reduced length of stay [prostate –0.44 (95% confidence interval –0.55 to –0.34) days; bladder –0.563 (95% confidence interval –4.30 to –0.83) days; renal –1.20 (95% confidence interval –1.57 to –0.82) days]. The centralisation meant that renal patients had an increased probability of receiving non-invasive surgery (0.05, 95% confidence interval 0.02 to 0.08). We found no evidence of impact on mortality or re-admissions, possibly because risk was already low pre-centralisation. London Cancer’s prostate, oesophago-gastric and bladder centralisations had medium probabilities (79%, 62% and 49%, respectively) of being cost-effective, and centralising renal services was not cost-effective (12% probability), at the £30,000/quality-adjusted life-year threshold. Qualitative analysis, implementation and outcomes – London Cancer’s provider-led network overcame local resistance by distributing leadership throughout the system. Important facilitators included consistent clinical leadership and transparent governance processes. Greater Manchester Cancer’s change leaders learned from history to deliver the oesophago-gastric centralisation. Greater Manchester Cancer’s urology centralisations were not implemented because of local concerns about the service model and local clinician disengagement. London Cancer’s network continued to develop post implementation. Consistent clinical leadership helped to build shared priorities and collaboration. Information technology difficulties had implications for interorganisational communication and how reliably data follow the patient. London Cancer’s bidding processes and hierarchical service model meant that staff reported feelings of loss and a perceived ‘us and them’ culture. Workshop – our findings resonated with workshop attendees, highlighting issues about change leadership, stakeholder collaboration and implications for future change and evaluation. The discrete choice experiment used a convenience sample, limiting generalisability. Greater Manchester Cancer implementation delays meant that we could study the impact of only London Cancer changes. We could not analyse patient experience, quality of life or functional outcomes that were important to patients (e.g. continence). Future research may focus on impact of change on care options offered, patient experience, functional outcomes and long-term sustainability. Studying other approaches to achieving high-volume services would be valuable. National Institute for Health and Care Research (NIHR) Clinical Research Network Portfolio reference 19761. This project was funded by the NIHR Health and Social Care Delivery Research programme and will be published in full in Health and Social Care Delivery Research; Vol. 11, No. 2. See the NIHR Journals Library website for further project information.
英格兰两个地区癌症专科手术服务的集中化:RESPECT-21混合方法评估
集中癌症专科手术服务是重大制度变革的一个例子。建议高容量中心改善癌症专科手术的护理和结果。我们的目的是使用混合方法来评估英国两个地区前列腺癌、膀胱癌、肾癌和食管胃癌专科手术的集中性[即伦敦癌症(英国伦敦),涵盖伦敦市中心北部、伦敦东北部和埃塞克斯郡西部,以及大曼彻斯特癌症(英国曼彻斯特),涵盖大曼彻斯特]。使用离散选择实验分析利益相关者对集中癌症专科手术的偏好,调查癌症患者(n = 206),保健专业人员(n = 111)和公众(n = 127)。采用前后对照设计对护理、结果和成本效益的影响进行定量分析。采用多站点案例研究设计对变革的实施和结果进行定性分析,分析文件(n = 873),访谈(n = 212)和非参与者观察(n = 182)。为了了解课程如何在其他情况下应用,我们与来自各种环境的利益相关者进行了一次在线研讨会。一个基于理论的框架被用来综合这些方法。利益相关者的偏好——患者、医疗保健专业人员和公众有类似的偏好,优先考虑降低并发症和死亡风险,以及更好地接触专家团队。旅行时间被认为是最不重要的。定量分析(变化的影响)——只有伦敦癌症的集中化发生得足够快,可以进行分析。这些变化与更少的外科医生做更多的手术和缩短的住院时间有关[前列腺-0.44(95%置信区间-0.55至-0.34)天;膀胱-0.563(95%可信区间4.30至-0.83)天;肾脏1.20(95%置信间隔1.57至-0.82)天]。集中治疗意味着肾脏患者接受非侵入性手术的概率增加(0.05,95%置信区间0.02至0.08)。我们没有发现对死亡率或再次入院有影响的证据,可能是因为集中治疗前的风险已经很低。伦敦癌症的前列腺、食道-胃和膀胱中心化具有中等的成本效益概率(分别为79%、62%和49%),在30000英镑/质量调整后的寿命阈值下,中心化肾脏服务不具有成本效益(12%的概率)。定性分析、实施和结果——伦敦癌症的供应商领导网络通过在整个系统中分配领导权,克服了当地的阻力。重要的促进者包括一贯的临床领导和透明的治理流程。大曼彻斯特癌症的变革领袖们从历史中吸取教训,实现了食道-胃的集中化。由于当地对服务模式的担忧和当地临床医生的脱离,大曼彻斯特癌症的泌尿外科中心化没有实施。伦敦癌症的网络在实施后继续发展。始终如一的临床领导有助于建立共同的优先事项和协作。信息技术的困难对组织间的沟通以及数据跟踪患者的可靠性产生了影响。伦敦癌症的投标流程和分级服务模式意味着员工报告了损失感和“我们和他们”的文化。研讨会——我们的发现引起了与会者的共鸣,强调了变革领导力、利益相关者合作以及对未来变革和评估的影响等问题。离散选择实验使用了一个方便的样本,限制了泛化能力。大曼彻斯特癌症实施延迟意味着我们只能研究伦敦癌症变化的影响。我们无法分析对患者重要的患者体验、生活质量或功能结果(如失禁)。未来的研究可能侧重于变化对所提供的护理选择、患者体验、功能结果和长期可持续性的影响。研究实现高容量服务的其他方法将是有价值的。美国国家卫生与保健研究所(NIHR)临床研究网络参考资料集19761。该项目由美国国立卫生研究院健康和社会护理提供研究计划资助,并将在《健康和社会保健提供研究》上全文发表;第11卷第2期。有关更多项目信息,请访问NIHR期刊图书馆网站。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.00
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信